outperform price
return enterpris jedi
result show make progress blow
death fragment health care provis integr
plan continu apac continu progress
integr care/servic provis program uptak
synergi given execut thu far see return
lsd ep growth emin achiev model
would higher ex-hif return
acceler msd even post today move
write market still impli neg
perpetu growth rate view sever given
estim increas year improv valuat
impli rais pt
ebitda reiter outperform rate stock
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
maintain adjust oper incom rang health benefit busi
narrow adjust op incom rang retail segment
health benefit lowest adjust op come quarter given season includ spend
support jan readi medicar busi
higher sequenti spend transform program
given time close aet prior year includ full impact share dilut
detail perform line compani expect
pharmaci growth driven net new busi specialti relat ingeniorx onboard continu
adopt mainten choic
benefit lower interest expens
growth driven addit aet higher volum retail segment pbm
retail script share increas bp yoy
experienc larger expect benefit gener launch primarili specialti improv
shift aet mail order specialti oper improv purchas econom
partial off-set continu price compress
result mm charg retail segment
made decis close retail pharmaci store major near end leas term
retail long term care oper incom declin driven reimburs pressur partial offset
declin continu script growth front store margin improv benefit gener
improv
saw modest improv lower end middl market commerci book vs last
track addit metro area hub year end end oper
store year end
perform slightli better
houston health hub outperform control group higher script volum mc visit higher front store
sale traffic store margin
dont expect materi impact
growth specialti
renew fehbp decemb
strong volum mainten choic program
gross new busi bn new busi improv bn
move onto phase chronic kidney care manag program face face counsel around differ
chemo dialysi clinic trial progress expect first two site activ confid trial
complet previous discuss timelin
 billion gener biosimilar come market
valuat methodolog base mix discount cash flow analysi rel valuat multipl
potenti elev govern scrutini drug price transpar neg impact long-
potenti on-line competit amazon erod front end comp margin us
continu reimburs pressur us eu hit ultim lead total margin
laboratori corp america
articl articl
time dissemin novemb
analyst elizabeth anderson suzi yoon michael newshel primarili respons prepar research report attest
follow view opinion render research report reflect person view subject compani
issuer part research analyst compens directli relat specif recommend view
research report
